The discovery of a previously unknown protein, gasdermin D (GSDMD), as the key effector that leads to pyroptosis and NETosis has created much excitement. Since its initial report in Oct. 2015, more than 200 papers have been published on studies of the structure and mechanism of GSDMD and its homologues. The clear connection between infection and inflammasome activation made GSDMD a promising target for the development of anti-infection treatment. In this mini review, we discuss first the current understanding of the structure and mechanism of GSDMD, focusing on its potential as a druggable target, and then recent efforts in the development of inhibitors to interfere with the pore-forming function of GSDMD and thus alleviate the detrimental effects due to pyroptotic cell death.
|Number of pages||8|
|State||Published - 2019|
Bibliographical noteFunding Information:
Y. W. is supported by AHA Great Rivers Affiliate Grant-in-Aid 17GRNT33410327, NSF CHE-1709381, and NIH, NIAID, R56AI137020 and R21AI142063. Z. L. is supported by NIH, NHLBI, HL123927.
© 2018 The Royal Society of Chemistry.
ASJC Scopus subject areas
- Molecular Medicine
- Pharmaceutical Science
- Drug Discovery
- Organic Chemistry